Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results.
The Brisbane, California company reported a cash position of $318.2 million as of March 31, which management believes is sufficient to fund operations into 2025.
Research and development costs were $27.8 million, compared to $15 million in the same period of 2022. The uptick was due to additional employee compensation costs, as well as clinical trial and pre-commercial manufacturing activities related to the company’s lead brain tumor treatment candidate, tovorafenib.
Day One stock improved 16% to $14.39.
“We are excited about our upcoming milestones, including the opportunity to share new clinical data from the FIREFLY-1 trial in an oral presentation at ASCO,” CEO Jeremy Bender said in a statement.
Day One’s net loss was $42.4 million in the quarter, with a non-cash stock compensation expense of $9.4 million, compared to $27.7 million with a non-cash stock compensation expense of $6.2 million a year earlier.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel